Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-15T15:24:23.223Z Has data issue: false hasContentIssue false
  • English
  • Français

Augmentation of Antidepressant Pharmacotherapy: A Preclinical Approach Using the Mouse Forced Swimming Test

Published online by Cambridge University Press:  07 November 2014

John P. Redrobe  and
Michel Bourin
Get access Rights & Permissions [Opens in a new window]

Abstract

Until recently, several weeks of treatment were required in order to obtain a clinically significant antidepressant response using pharmacotherapy. The present study, using the mouse forced swimming test, investigated possible antidepressant augmentation strategies, together with the probable mechanisms involved in such potentiations. It is clear from this and other similar studies that it is possible to enhance the activity of antidepressant drugs with the addition of other compounds (ie, clonidine, quinine, glyburide, pindolol, or buspirone). These data indicate that direct/indirect manipulation of serotonergic receptor systems potentiates the effect antidepressant drugs (ie, selective serotonergic reuptake inhibitors) in the mouse forced swimming test, and thus establish this model as a reliable preclinical tool for the investigation of possible antidepressant augmentation strategies. It also appears that this model can be used as a method for identifying the mechanisms involved in such treatment strategies.

Type
Feature Articles
Information
CNS Spectrums , Volume 4 , Issue 4: Psychiatric Aspects of Medical Illness , April 1999 , pp. 73 - 82
Copyright
Copyright © Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Porsolt, RD, Bertin, A, Jalfre, M. Behavioural despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327–336.Google ScholarPubMed
2.Borsini, F, Meli, A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology. 1988;94:147–160.CrossRefGoogle Scholar
3.Borsini, F. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev. 1995;19:377–395.CrossRefGoogle ScholarPubMed
4.Porsolt, RD, Anton, G, Blavet, N, Jalfre, M. Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol. 1978;47:379–391.CrossRefGoogle ScholarPubMed
5.Porsolt, RD, Bertin, A, Blavet, N, Deniel, M, Jalfre, M. Immobility induced by forced swimming in rats: effects of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol. 1979;57:201–210.CrossRefGoogle ScholarPubMed
6.Detke, MJ, Wieland, S, Lucki, I. Blockade of the antidepressant-like effects of 8-OH-DPAT, buspirone and desipramine in the rat forced swim test by 5-HT1A receptor antagonists. Psychopharmacology (Berl). 1995;119:47–54.CrossRefGoogle ScholarPubMed
7.Heal, DJ, Lister, S, Smith, SL, Davies, CL, Molyneux, SG, Green, AR. The effects of acute and repeated administration of various antidepressant drugs on clonidine-induced hypoactivity in mice and rats. Neuropharmacology. 1983;22:983–992.CrossRefGoogle ScholarPubMed
8.Racagni, G, Brunello, N, Mocheti, I, Cagiano, R, Cuomo, V. Presynaptic and transynaptic mechanisms involved in the sub-sensitivity of rat cortical noradrenergic system after long-term antidepressant treatment. Acta Pharmacol Toxicol. 1985;56,190–197.CrossRefGoogle Scholar
9.Malinge, M, Bourin, M, Colombel, MC, Larousse, C. Additive effects of clonidine and antidepressant drugs in the mouse forced-swimming test. Psychopharmacology (Berl). 1988;96:104–109.CrossRefGoogle ScholarPubMed
10.Bourin, M, Colombel, MC, Malinge, M, Bradwejn, J. Clonidine as a sensitizing agent in the forced swimming test for revealing antidepressant activity. J Psychiatry Neurosci. 1991;16:199–203.Google ScholarPubMed
11.Mongeau, R, Blier, P, de Montigny, C. In vivo electrophysiological evidence for tonic activation by endogenous noradrenaline of alpha 2-adrenoceptors on 5-hydroxytryptamine terminals in the rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:266–272.CrossRefGoogle ScholarPubMed
12.Bourin, M, Hascoet, M, Colombel, MC, Redrobe, JP, Baker, GB. Differential effects of clonidine, lithium and quinine in the forced swimming test in mice for antidepressants: possible roles of serotonergic systems. Eur Neuropsychopharmacol. 1996;6:231–236.CrossRefGoogle Scholar
13.Redrobe, JP, Bourin, M. Effects of pretreatment with clonidine, lithium and quinine on the activities of antidepressant drugs in the mouse tail suspension test. Fundam Clin Pharmacol. 1997;11:381–386.CrossRefGoogle ScholarPubMed
14.Redrobe, JP, Bourin, M. Clonidine potentiates the effects of 5-HT1A, 5-HT1B and 5-HT2A/2C antagonists and 8-OH-DPAT in the mouse forced swimming test. Eur Neuropsychopharmacol. 1998,138:198–206.Google Scholar
15.Katz, B, Miledi, R. Tetrodotoxin-resistant electric activity in presynaptic terminals. J Physiol (Lond). 1969;203:459–487.CrossRefGoogle ScholarPubMed
16.Benoit, PR, Mambrini, J. Modification of transmitter release by ions which prolong the presynaptic action potential. J Physiol (Lond). 1970;210:681–695.CrossRefGoogle ScholarPubMed
17.Kumamoto, E, Kuba, K. Effects of K+ -channel blockers on neurotransmitter release in bullfrog sympathetic ganglia. J Pharmacol Exp Ther. 1985;235:241–247.Google ScholarPubMed
18.Guo, WY, Todd, KG, Bourin, M, Hascoet, M. The additive effects of quinine on antidepressant drugs in the forced swimming test in mice. Psychopharmacology (Berl). 1995;121:173–179.CrossRefGoogle ScholarPubMed
19.Guo, WY, Todd, KG, Bourin, M, Hascoet, M, Kouadio, F. Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol Biochem Behav. 1996;54:725–730.CrossRefGoogle ScholarPubMed
20.Yakel, JL, Shao, XM, Jackson, MB. The selectivity of the channel coupled to the 5-HT3 receptor. Brain Res. 1990;533:46–52.CrossRefGoogle Scholar
21.Redrobe, JP, Pinot, P, Bourin, M. The effect of the potassium channel activator, cromakalim, on antidepressant drugs in the forced swimming test in mice. Fundam Clin Pharmacol. 1996;10:524–528.CrossRefGoogle ScholarPubMed
22.Redrobe, JP, MacSweeney, CP, Bourin, M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 1996;318:213–220.CrossRefGoogle ScholarPubMed
23.de Montigny, C, Chaput, Y, Blier, P. Classical and novel targets for antidepressant drugs. Int Acad Biomed Drug Res. 1993;5:8–17.Google Scholar
24.Tome, MB, Isaac, MT, Harte, R, Holland, C. Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressanl latency. Int Clin Psychopharmacol. 1997;12:81–90.CrossRefGoogle ScholarPubMed
25.Blier, P, Bergeron, R. Early onset of therapeutic action in depression and greater efficacy of antidepressant treatments: are they related? Int Clin Psychopharmacol. 1997;12(suppl 3):S21–S28.CrossRefGoogle ScholarPubMed
26.Blier, P, Bergeron, R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15:217–222.CrossRefGoogle ScholarPubMed
27.Bourin, M, Redrobe, JP, Baker, GB. Pindolol does not act only on 5-HT1A receptors in augmenting antidepressant activity in the mouse forced swimming test. Psychopharmacology (Berl). 1998;136:226–234.CrossRefGoogle Scholar
28.Artigas, F, Romero, L, de Montigny, C, Blier, P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 1996;19:378–383.CrossRefGoogle ScholarPubMed
29.Redrobe, JP, Bourin, M. Dose-dependent influence of buspirone on the activities of selective serotonin reuptake inhibitors in the mouse forced swimming test. Psychopharmacology (Berl). 1998;138:198–206.CrossRefGoogle ScholarPubMed
30.Joffe, RT, Schuller, DR. An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry. 1993;54:269–271.Google ScholarPubMed
31.Jacobsen, FM. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991;52:217–220.Google ScholarPubMed
32.Hoyer, D. Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res. 1988;8:59–81.CrossRefGoogle ScholarPubMed
33.Hjorth, S. (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine. Eur J Pharmacol. 1996;303:183–186.CrossRefGoogle Scholar
34.Hascoet, M, Bourin, M, Khimake, S. Additive effect of lithium and clonidine with 5-HT1A agonists in the forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry. 1994;18:381–396.CrossRefGoogle ScholarPubMed
35.Cervo, L, Samanin, R. Potential antidepressant properties of 8-hydroxy-2-(di-n-propylamino)tetralin, a selective serotonin1A receptor agonist. Eur J Pharmacol. 1987;144:223–229.CrossRefGoogle ScholarPubMed
36.Giral, P, Martin, P, Soubrie, P, Simon, P. Reversal of helpless behavior in rats by putative 5-HT1A agonists. Biol Psychiatry. 1988;23:237–242.CrossRefGoogle ScholarPubMed
37.Kennett, GA, Dickson, SL, Curzon, G. Enhancement of some 5-HT-dependent behavioral responses following repeated immobilization in rats. Brain Res. 1985;330:253–263.CrossRefGoogle ScholarPubMed
38.Kennett, GA, Curzon, G. Mechanism of action of 8-OH-DPAT on a rat model of human depression. In: Bevan, P, Cools, A, Archer, T, Lawrence, S, eds. Behavioral Pharmacology of 5-HT. L. Erlbaum Associates Publishing; Mahurah, NJ: 1989:225–229.Google Scholar
39.Robinson, DS, Alms, DR, Shrotriya, RC, Messina, ME, Wickramaratre, P. Serotonergic anxiolytics and treatment of depression. Psychopathology. 1989;22(suppl 1):22–36.CrossRefGoogle ScholarPubMed
40.Przegalinski, E, Moryl, E, Papp, M. The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression. Neuropharmacology. 1995;34:1305–1310.CrossRefGoogle Scholar
41.Martin, P. 1-(2-pyrimidinyl)-piperazine may alter the effects of the 5-HT1A agonists in the learned helplessness paradigm in rats. Psychopharmacology (Berl). 1991;104:275–278.CrossRefGoogle ScholarPubMed
42.Da Rocha, MA, Puech, AJ, Thiébot, MH. Influence of anxiolytic drugs on the effects of specific serotonin reuptake inhibitors in the forced swimming test in mice. J Psychopharmacol (Oxf). 1997;11:211–218.CrossRefGoogle ScholarPubMed
43.Jajoo, HK, Mayol, RF, Labudde, JA, Blair, IA. Metabolism of the antianxiety drug buspirone in the rat. Drug Metab Dispos. 1989;17:625–633.Google ScholarPubMed
44.Caccia, S, Fong, MH, Guiso, G. Disposition of the psychotropic drugs buspirone, MJ-13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica. 1985;15:835–844.CrossRefGoogle ScholarPubMed
45.Caccia, S, Conti, I, Vigano, G, Garattini, S. 1-(2-pyrimidinyl)-piperazine as active metabolite of buspirone in man and rat. Pharmacology. 1986;33:46–51.CrossRefGoogle ScholarPubMed
46.Cervo, L, Grignaschi, G, Samanin, R. Alpha 2-adrenoreceptor blockade prevents the effect of desipramine in the forced swimming test. Eur J Pharmacol. 1990;175:301–307.CrossRefGoogle Scholar
47.Rimele, TJ, Henry, DE, Lee, DKH, Geiger, G, Heaslip, RJ, Grimes, D. Tissue-dependent alpha-adrenoreceptor activity of buspirone and related compounds. J Pharmacol Exp Ther. 1987;241:771–778.Google Scholar